Eli Lilly CEO Aims to Break the Drug Industry's Boom-Bust Cycle

When Dave Ricks took over as CEO of Eli Lilly & Co. in 2017, the pharmaceutical industry was facing a difficult period. Americans trusted drug companies less than airlines, law firms, and even the federal government. Then-President Donald Trump harshly criticized these companies for high prices. Rising costs had increased reports of some diabetes patients rationing their insulin. Ricks, the 11th CEO in Lilly's 150-year history, acknowledged this was a public relations nightmare. Nearly a decade later, the atmosphere at Lilly has changed significantly. The company's diabetes drug Mounjaro and obesity drug Zepbound have transformed both the company's fortunes and its public image. This success is seen as part of a strategy to break the typical boom-bust cycle in the pharmaceutical industry. Bloomberg News Health Reporter Madison Muller examines the details of this transformation. Under Ricks' leadership, Lilly aims to become more resilient to industry fluctuations through its innovative drug portfolio. The company's focus is on sustainable growth and improving patient access. This is not investment advice.